Archive for the 'Upper gastrointestinal symptoms' Category

27 Sep

Persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: Psychometric validity (Part 5)

For PASS test responders, a large overall treatment effect was associated with an effect size of -2.95 (-3.67/1.24) and -3.22 (-3.90/1.21) for the English and French groups, respectively. After patients switched their PPI medication at visit 2, 54% (77 of 142) in the English-speaking group and 69% (74 of 107) in the French-speaking group experienced […]

26 Sep

Persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: Psychometric validity (Part 4)

Responsiveness and discriminant validity The PASS results showed that 42 (30%) and 35 (33%) patients in the English- and French-speaking groups, respectively, were ‘PASS test responders’ on a per protocol analysis; ie, they had complete resolution of their symptoms (PASS test score 0) at the end of treatment. Most of the effect sizes for individual […]

25 Sep

Persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: Psychometric validity (Part 3) / generic vardenafil online

Construct validity The PASS test scores were compared with baseline scores for the comparator scales (GSRS, QoLRAD and RDQ) to evaluate construct validity (Table 1). The PASS test score from visit 2 showed moderate-to-high correlation with the overall GSRS scale in both languages (0.51 and 0.43) and moderate QoLRAD correlation (0.38 to 0.57) depending on the […]

24 Sep

Persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: Psychometric validity (Part 2)

Mean total PASS scores were 3.5 (SD 1.2) and 3.4 (SD 1.4) for visits 1 and 2, respectively, in the English group; and 3.4 (SD 1.2) and 3.3 (SD 1.3), respectively, in the French group. After the four-week treatment, at visit 3, the mean total PASS scores had fallen to 2.0 (SD 1.7) and 1.7 […]

23 Sep

Persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: Psychometric validity (Part 1)

The term ‘stomach problems’ for question 1 was considered adequate by 65% (13 of 20) of the English- and 67% (eight of 12) of the French-speaking patients to describe their symptoms. Demographics and baseline characteristics Overall, 158 English-speaking patients (mean age 56 years, 41% male) and 113 French-speaking patients (mean age 58 years, 31% male) […]

22 Sep

Persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: Results (Part 2)

The main stomach symptom(s) were described as bloating, heartburn, flatulence or gas, regurgitation and discomfort by 75% (15 of 20) and 92% (11 of 12) of the English- and Frenchspeaking groups, respectively. These are consistent with those listed as possible symptoms in the PASS test. The words ‘stomach pain or discomfort’ and ‘heartburn’ were well-understood […]

21 Sep

Persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: Results (Part 1)

An overview of the validation process for the PASS test is provided in Figure 2. Initial identification of symptoms and potential PASS questions Analysis of the telephone survey, completed by 150 patients, indicated that 47% of patients supplemented their PPI with an over-the-counter medication. Stomach-related problems reported by these patients included sleeping (50%), eating (47%), […]

20 Sep

Persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: Responsiveness and discriminant power

Patients were also classified after four weeks of treatment as PASS test responders (visit 3 PASS score 0) or PASS test nonresponders (visit 3 PASS score greater than 0). For the analysis, the OTE was collapsed into four different categories: no change (OTE equals -1, 0, +1); small change (OTE equals -3, -2, +2, +3); […]

19 Sep

Persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: Construct validity

For PASS inter-item analysis, individual phi correlation coefficients were calculated. Correlations were considered low-to-moderate if the coefficients fell between 0.4 and 0.6; moderate-to-high if greater than 0.6; and excellent if greater than 0.8. Construct validity refers to how well the patient’s status is reflected by the PASS test compared with other standard questionnaires. It is […]

18 Sep

Persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: Test-retest reliability

The OTE is a 15-point scale that measures the magnitude of change in health status (-7 to -1 is worse; 0 is no change; and 1 to 7 is better). Subjects were first asked to report their symptoms as improved, about the same, or worse when compared with the previous visit. If changed, patients had […]

© 2017 - Men’s Health Info Blog